DOCSLIB.ORG

Brain Serotonin Metabolism After Tolerance Okod Dosageoflsd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Brain Serotonin Metabolism After Tolerance Okod Dosageoflsd Advances in Biochemical Psychopharmacology, Vol. 10 Raven Press, New York © 1974 Brain Serotonin Metabolism After Tolerance _6-557. okod DosageofLSD rties of m istry, reening Daniel X. Freedman and WilliamO. Boggan Neuro- d high University of Chicago, Chicago, Illinois 6"0637 d cord. Ltbrain :646m I. INTRODUCTION of t, _rnalian Some 15 years ago we studied tolerance to LSD (Freedman, •hal_zymicof Aghajanian, Ornitz, and Rosner, 1958) because of intrinsic interest and as a "lever" to aid in defining the role of neurohumors and mechanisms Le_ay. of LSD action. Operationally, tolerance is a decrement of effect _phrine contingent upon prior dosage schedule; the mechanisms axe obscure. ;6-467. With appropriate behavioral measures in rat, we observe a diminished H and response intensity or duration, or both, after daily doses of LSD; alciumemical increased dosage restores the initial response. A less distinct "short- term" tolerance occurs with LSD at hourly intervals (Freedman and f brain Aghajanian, 1959). 'sRavenycho- Tolerance is not "absolute"; there is an interaction of dosage, behavioral task, and drug effect (Freedman, Appel, Haxtman, and fitters. Molliver, 1964a). In the rat, sympathomimetic effects (mydriasis, 5strate piloerection, pyrexia), EEG alerting, and hind-limb ataxia (lasting 45 to don in 60 min after moderate doses) show tolermnce; centrally mediated parasympathomimetic effects (salivation and bradycardia--lasting 90 ?",NewJ- J--- min or more) do not (Freedman et al., 1958). Tolerance is not evident with noxious reinforcement such as escape behavior (Appel, 1968; '. aasay Hamilton, 1960). Thera- In man, subjective and sympathomimetic effects of 200 pg or less of dne in LSD are absent by the thh'd or fourth daily dose and return after 3 or 4 them- days of abstinence. In the rat, a behavioral effect gradually diminishes mid is clear-cut after foul" to seven daily doses; full sensitivity returns ctricalLmino- after 3 or 4 drug-free days. The "acute" effect is a tendency to cease responding for 30 to 45 min immediately after 130 pg/kg of LSD amine (longer periods with higher dosage m_d shorter periods with lower :.yand dosage). Positive reinforcement (food) seems not as '"mterestmo"_,'",the animal can, but is not disposed to exert organized behavior under these 151 L_ 152 5-HT METABOLISM AFTER LSD contingencies (Appel, Whitehead, and Freedman, 1968). A simple at 9:30 a.m. on food-rew_ded F-R schedule demonstrates the temporal characteristics differences in of this dose-contingent tolerance and cross tolerance of LSD, tryptophan was psilocybin, and mescaline (Freedman and Aghajanian, 1959; Appel and Lewander, 197( Freedman, 1968). Conceptually, "periods" of neurochemJcal change after drug injection may be correlated with the occurrence, intensity, and duration of different physiological and behavioral responses. A significant period for such correlation is the first 60 min after a The results s: single dose of LSD. There is an increase of 12 to 20% of 5-hydroxy- X 7 occurs dis -- tryptamine (5-HT) localized in the particulate fraction of whole brain This shift of th (Freedman, 1961a), and further to a vesicle-rich fraction (Halaris, doses of LSDq Lovetl, and Freedman, 1972; Halaris and Lovell, 1973); a slight were acting lik( decrease in norepinephrine (Freedman, 1961b; Freedman, Barchas, and 5-HIAA (30 mi Schoenbrun, 1962; Freedman, 1963); a decrease in 5-hydroxy- 60 minis inter: indoleacetic acid (5-HIAA) and slowed turnover (Lovell, Rosecrans, and in time, this Freedman, 1967; Rosecrans, Lovell, and Freedman, 1967; Diaz, Ngai, tryptophan in I and Costa, 1968; And6n, Corrodi, Fuxe, and Hokfelt, 1968; And_n, to L X 1 (Bo! Corrodi, and Fuxe, 1971); a small increase of brain tryptophan (Tonge diminished rest and Leonard, 1970; Boggan and Freedman, 1973); brain levels of response of tr3 drug--following the plasma--arrive at half-life values by 45 min daily doses of: (Freedman, Aghajanian, and Coquet, 1964b; Freedman and Coquet, metabolism wit 1965; Freedman, 1966); raphe firing is inhibited with roughly similar onset and duration as the amine changes (Aghajanian, Foote, and Sheard, 1970). Synthesis is decreased (Lin, Ngai, and Costa, 1969; Schubert, Nyback, and Sedvall, 1970; Shields and Eccleston, 1973) as The increas, early as 21 min after drug (Shields and Eccleston, 1973), and recently, decreased syn we find, at 15 min after drug. The increased 5-HT, decreased 5-HIAA, Huttunen (197 and clearance of drug peak at the termination of the "acute" behavioral multiple oral ( effects. The 5-HT and 5-HIAA effect occurs with psychotomimetic when there are indoles but not with phenylethylamines or nonpsychotomimetic reduced turnov congeners(Freedman, Gottlieb, and Lovell,1970). It now seel We now report initial attempts to determine whether indole tolerance dosa_ metabolism changes with tolerance dosage schedules during tim same the earlier pe_ period that physiological and behavioral effects show tolerance. We find tryptophan at significant alterations in brain 5-HT, 5-HIAA, and tryptophan concen- events seem t tration after daily administration of LSD, as preliminarily reported by dissimilar to BogganandFreedman(1973). (Freedmanet effects and pea II.METHOD Aftera singl (1) cessation Male Sprague-Dawley rats (175 to 250 g) were randomly divided into mentalization , three equal groups: (1) S X 7--daily saline for 7 days; (2) L X 1--saline whatever the for 6 days and LSD (520 pg/kg) on the seventh day; and (3) L X (3) undefined 7--LSD (520 pg/kg) daily for 7 days. Injections were at 5:00 p.m. and inhibition (Fr_ ! 5-IIT METABOLISM AFTER LSD 153 ple at 9:30 a.m. on the day of sacrifice. The groups showed no significant tics differences in weight. Analysis of whole-brain 5-HT, 5-HIAA, and _D, tryptophan was then done (And_n and Magnusson, 1967; Jonsson and md Lewander, 1970; Denckta and Dewey, 1967). r!_je ity, III. RESULTS _r a The results show the following: (1) The peak elevation of 5-HT in L xy- × 7 occurs distinctly earlier than for L × 1 (30 vs. 45 min) (Fig. 1). ain This shift of the 5-HT peak "to the left" also occurs with single lower ris, - doses of LSD (Rosecrans et al., 1967) (as expected if multiple doses _ht were acting like a single smaller dose). (2) The time of peak decrease in md 5-HIAA (30 min) is the same, but the concentration in L X 7 at 45 and xy- 60 rain is intermediate--between controls and L X 1; ra_her than a shift md in time, this represents a diminished response. (3)By 60 min, _ai, tryptophan in L X 7 returns to control concentrations--in sharp contrast, en, to L X 1 (Boggan and Freedman, 1973). As with 5-HIAA, this is a _ge diminished response to multiple doses. We now find similarly reduced of response of tryptophan after three daily doses of 520 pg/kg or seven nin daily doses of 260 pg/kg. We, as Winter (1971), find no change in drug ,et, metabolism with tolerance dosage. [lar md IV. COMMENT 39; as The increase in brain tryptophan after LSD, during a time of ly, decreased synthesis, will require future examination. Diaz and ,A, Huttunen (1971) showed an increase in turnover 13 hr after the last of ral multiple oral doses (20 /_g/kg); the general question is whether and tic when there are compensatory changes after one or several episodes of tic - reduced turnover. It now seems evident that there are neurochemieal responses to _le tolerance dosage schedules of LSD, manifest both in shifts in time (e.g., .he the earlier peak of 5-HT) and in magnitude (e.g., the differences in nd tryptophan at 60 min and the 5-HIAA at 45 and 60 min). In general, m- events seem to occur more ra_idly and to terminate sooner--not by dissimilar to what is obselwed in behavioral tests of tolerance (Freedman et al., 1964a). Termination of certain acute behavioral effects and peak changes in 5-HT seems roughly correlated. After a single dose of LSD, the mechanisms affecting indoles include _1) cessation of raphe neuronal firing; (2) "binding" or compart- to mentalization of 5-HT (an increase of no more than 100 ng/gm brain, ne whatever the dosage) almost specifically in nerxe-ending vesicles; X _3) undefined inaccessibility to MAO without evidence of direct nd inhibition (Freedman, 1961a; Freedman et al., 1970; Collins, Lovell, 154 5-HT METABOLISM AFTER LSD 125- _ L x7 Thed, O I.SD ma 120- -. -- [] [] TP, Lxl r,x',.ptor ",/" _\ _ TP, Lx7 ,I_...nces. 115- _..........o \\ * p < .05 _..!_:vior: Ct' . _ a:l_)ther , %, 5 - HT h<n and 1 10- __ _,-, ()ther .__ \v ........ ,,,.._ ntphe eel 0 105- after re_ or" wtraben: I-- Z }"rt.edllla: _j _ the fact O 100 . ltF/0b) }, O n it't.;.l}_O[_,: LI_ to attvtr_l O 95 m'tion, :..rotonin 90- 85- A_i'taF_ntw • 5-HIAA -- (_lo_y d dJ,'Lh)l_ L,f," .'_'<" At:d.rL N 75 1; 5'0 4'5 6'0 7'5 9'0 105 120 ,,,,.,;,, [Aru,t,-n, N TIME (MIN) OF SACRIFICE AFTER LAST INJECTION :.,.,.,..,., J.*t_r_:.N FIG. 1. Effect of multiple and single injections of LSD (520 #g/kg} on rat brain 5-HT, 5-HIAA, An,t," ) .% and tryptophan. Control valuesfor 5-HT and 5-HIAA are as follows (mean and standarderror in nanograms per gram): 5-HT, 502.t ± 5.1; 5-HIAA, 321.5 -+3.9. The control value for d,.t,._m_ tryptophan (mean _ standard error in micrograms/gram) is 4.96 + 0.06. The number of animals _:_ ;(J _ - ,%p;,,.! J used wasat least 20 per group per time point.
Load more

Recommended publications
  • Serotonin Functioning and Adolescents' Alcohol
    Development and Psychopathology, 2017, page 1 of 21 # Cambridge University Press 2017 doi:10.1017/S095457941700058X Serotonin functioning and adolescents’ alcohol use: A genetically informed study examining mechanisms of risk FRANCES L. WANG,a LAURIE CHASSIN,a JOHN E. BATES,b DANIELLE DICK,c JENNIFER E. LANSFORD,d e d GREGORY S. PETTIT, AND KENNETH A. DODGE aArizona State University; bIndiana University Bloomington; cVirginia Commonwealth University; dDuke University; and eAuburn University Abstract The current study used data from two longitudinal samples to test whether self-regulation, depressive symptoms, and aggression/antisociality were mediators in the relation between a polygenic score indexing serotonin (5-HT) functioning and alcohol use in adolescence. The results from an independent genome-wide association study of 5-hydroxyindoleacetic acid in the cerebrospinal fluid were used to create 5-HT polygenic risk scores. Adolescents and/or parents reported on adolescents’ self-regulation (Time 1), depressive symptoms (Time 2), aggression/antisociality (Time 2), and alcohol use (Time 3). The results showed that 5-HT polygenic risk did not predict self-regulation. However, adolescents with higher levels of 5-HT polygenic risk showed greater depression and aggression/antisociality. Adolescents’ aggression/antisociality mediated the relation between 5-HT polygenic risk and later alcohol use. Deficits in self- regulation also predicted depression and aggression/antisociality, and indirectly predicted alcohol use through aggression/antisociality. Pathways to alcohol use were especially salient for males from families with low parental education in one of the two samples. The results provide insights into the longitudinal mechanisms underlying the relation between 5-HT functioning and alcohol use (i.e., earlier aggression/antisociality).
    [Show full text]
  • Tryptophan and 5-Hydroxytryptophan for Depression (Review)
    Cochrane Database of Systematic Reviews Tryptophan and 5-Hydroxytryptophan for depression (Review) Shaw KA, Turner J, Del Mar C Shaw KA, Turner J, Del Mar C. Tryptophan and 5-Hydroxytryptophan for depression. Cochrane Database of Systematic Reviews 2002, Issue 1. Art. No.: CD003198. DOI: 10.1002/14651858.CD003198. www.cochranelibrary.com Tryptophan and 5-Hydroxytryptophan for depression (Review) Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 4 DISCUSSION ..................................... 4 AUTHORS’CONCLUSIONS . 5 ACKNOWLEDGEMENTS . 5 REFERENCES ..................................... 6 CHARACTERISTICSOFSTUDIES . 10 DATAANDANALYSES. 15 Analysis 1.1. Comparison 1 L-Tryptophan and 5-HTP versus placebo for the treatment of depression, Outcome 1 Numbers ofresponders................................... 15 Analysis 2.1. Comparison 2 Side-effects of L-Tryptophan and 5-HTP versus placebo, Outcome 1 Numbers with side- effects. .................................... 16 FEEDBACK...................................... 16 WHAT’SNEW..................................... 16 HISTORY....................................... 17 CONTRIBUTIONSOFAUTHORS . 17 DECLARATIONSOFINTEREST . 17 SOURCESOFSUPPORT
    [Show full text]
  • Treating Smoking Dependence in Depressed Alcoholics
    Treating Smoking Dependence in Depressed Alcoholics Nassima Ait-Daoud, M.D.; Wendy J. Lynch, Ph.D.; J. Kim Penberthy, Ph.D.; Alison B. Breland, Ph.D.; Gabrielle R. Marzani-Nissen, M.D.; and Bankole A. Johnson, D.Sc., M.D., Ph.D. Alcoholism and nicotine dependence share many neurobiological underpinnings; the presence of one drug can cause a person to crave the other. Depressive illness can complicate comorbid alcohol and nicotine dependence by exacerbating the negative affect encountered during attempts to abstain from one or both drugs. Given the morbidity and mortality associated with cigarette smoking, it is imperative to identify treatments to promote smoking cessation and address comorbid psychiatric conditions contemporaneously. Pharmacotherapeutic options demonstrating varying degrees of efficacy and promise in preclinical and clinical studies include nicotine replacement therapy (NRT), selective serotonin reuptake inhibitors (SSRIs), bupropion, varenicline, tricyclic antidepressants, and bupropion plus NRT. Topiramate has shown potential for promoting smoking cessation in alcoholics, although its safety in depressed patients has not been fully explored. The efficacy of medications for treating nicotine dependence is generally enhanced by the inclusion of behavioral interventions such as cognitive behavioral therapy. When group cohesion and social support are stressed, success rates increase among depressed smokers undergoing smoking cessation treatment. Additional treatment strategies targeting dually dependent individuals with
    [Show full text]
  • L‐Tryptophan As the Origin of Psilocybe Natural Products
    Minireviews ChemPlusChem doi.org/10.1002/cplu.202000581 1 2 3 Taking Different Roads: l-Tryptophan as the Origin of 4 5 Psilocybe Natural Products 6 [a] [b] [b] [a] 7 Claudius Lenz, Alexander Sherwood, Robert Kargbo, and Dirk Hoffmeister* 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 ChemPlusChem 2021, 86, 28–35 28 © 2020 The Authors. ChemPlusChem published by Wiley-VCH GmbH Wiley VCH Mittwoch, 30.12.2020 2101 / 181786 [S. 28/35] 1 Minireviews ChemPlusChem doi.org/10.1002/cplu.202000581 1 Psychotropic fungi of the genus Psilocybe, colloquially referred highlighted. Psilocybin and its congeners, the heterogeneous 2 to as „magic mushrooms”, are best known for their l- blue-colored psilocyl oligomers, alongside β-carbolines and 3 tryptophan-derived major natural product, psilocybin. Yet, N,N-dimethyl-l-tryptophan, are presented as well as current 4 recent research has revealed a more diverse secondary knowledge on their biosynthesis is provided. The multidiscipli- 5 metabolism that originates from this amino acid. In this nary character of natural product research is demonstrated, and 6 minireview, the focus is laid on l-tryptophan and the various pharmacological, medicinal, ecological, biochemical, and evolu- 7 Psilocybe natural products and their metabolic routes are tionary aspects are included. 8 9 1. Introduction In this minireview, we focus on the biosynthetic routes of L- 10 tryptophan-derived natural products in Psilocybe mushrooms.
    [Show full text]
  • A Placebo Controlled Investigation of the Effects of Tryptophan Or Placebo on Subjective and Objective Measures of Fatigue
    European Journal of Clinical Nutrition (1998) 52, 425±431 ß 1998 Stockton Press. All rights reserved 0954±3007/98 $12.00 http://www.stockton-press.co.uk/ejcn A placebo controlled investigation of the effects of tryptophan or placebo on subjective and objective measures of fatigue A Cunliffe, OA Obeid and J Powell-Tuck Department of Human Nutrition, St Bartholomew's and Royal London School of Medicine and Dentistry, Queen Mary and West®eld College, London E1 2AD Objective: To examine the effect of L-tryptophan administration on subjective and objective measures of fatigue in healthy volunteers. Subjects: Six healthy volunteers (4M:2F) were recruited from staff and students at the College. Setting: Department of Human Nutrition, St. Bartholomews and the Royal London School of Medicine and Dentistry. Design: Subjects were tested for central and peripheral fatigue using a visual analogue scale, ¯icker fusion frequency, grip strength, reaction time and wrist ergometry. In addition, plasma free tryptophan concentrations and Trp:LNAA ratio were determined. Measurements were made before, and at 1, 2, 3 and 4 h after drinking one of two test drinks. The drinks were of either caffeine free diet Coca-Cola (placebo) or caffeine free diet Coca- Cola plus L-tryptophan (30 mg/kg: active drink). Each of the six subjects was tested after placebo and active drink with a one week washout period between test days. Results: Subjective fatigue was signi®cantly increased following tryptophan compared to placebo (P < 0.002), and objective measures of central fatigue were signi®cantly increased by tryptophan compared to placebo (¯icker fusion frequency: P < 0.001; reaction time P < 0.001).
    [Show full text]
  • Alcohol Dependence and Withdrawal Impair Serotonergic Regulation Of
    Research Articles: Cellular/Molecular Alcohol dependence and withdrawal impair serotonergic regulation of GABA transmission in the rat central nucleus of the amygdala https://doi.org/10.1523/JNEUROSCI.0733-20.2020 Cite as: J. Neurosci 2020; 10.1523/JNEUROSCI.0733-20.2020 Received: 30 March 2020 Revised: 8 July 2020 Accepted: 14 July 2020 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.jneurosci.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2020 the authors 1 Alcohol dependence and withdrawal impair serotonergic regulation of GABA 2 transmission in the rat central nucleus of the amygdala 3 Abbreviated title: Alcohol dependence impairs CeA regulation by 5-HT 4 Sophia Khom, Sarah A. Wolfe, Reesha R. Patel, Dean Kirson, David M. Hedges, Florence P. 5 Varodayan, Michal Bajo, and Marisa Roberto$ 6 The Scripps Research Institute, Department of Molecular Medicine, 10550 N. Torrey Pines 7 Road, La Jolla CA 92307 8 $To whom correspondence should be addressed: 9 Dr. Marisa Roberto 10 Department of Molecular Medicine 11 The Scripps Research Institute 12 10550 N. Torrey Pines Road, La Jolla, CA 92037 13 Tel: (858) 784-7262 Fax: (858) 784-7405 14 Email: [email protected] 15 16 Number of pages: 30 17 Number of figures: 7 18 Number of tables: 2 19 Number of words (Abstract): 250 20 Number of words (Introduction): 650 21 Number of words (Discussion): 1500 22 23 The authors declare no conflict of interest.
    [Show full text]
  • Hallucinogens: an Update
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Hallucinogens: An Update 146 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Hallucinogens: An Update Editors: Geraline C. Lin, Ph.D. National Institute on Drug Abuse Richard A. Glennon, Ph.D. Virginia Commonwealth University NIDA Research Monograph 146 1994 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Hallucinogens: An Update” held on July 13-14, 1992. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • N,N-Dimethyltryptamine Compound Found in the Hallucinogenic Tea Ayahuasca, Regulates Adult Neurogenesis in Vitro and in Vivo Jose A
    Morales-Garcia et al. Translational Psychiatry (2020) 10:331 https://doi.org/10.1038/s41398-020-01011-0 Translational Psychiatry ARTICLE Open Access N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo Jose A. Morales-Garcia 1,2,3,4, Javier Calleja-Conde 5, Jose A. Lopez-Moreno 5, Sandra Alonso-Gil1,2, Marina Sanz-SanCristobal1,2, Jordi Riba6 and Ana Perez-Castillo 1,2,4 Abstract N,N-dimethyltryptamine (DMT) is a component of the ayahuasca brew traditionally used for ritual and therapeutic purposes across several South American countries. Here, we have examined, in vitro and vivo, the potential neurogenic effect of DMT. Our results demonstrate that DMT administration activates the main adult neurogenic niche, the subgranular zone of the dentate gyrus of the hippocampus, promoting newly generated neurons in the granular zone. Moreover, these mice performed better, compared to control non-treated animals, in memory tests, which suggest a functional relevance for the DMT-induced new production of neurons in the hippocampus. Interestingly, the neurogenic effect of DMT appears to involve signaling via sigma-1 receptor (S1R) activation since S1R antagonist blocked the neurogenic effect. Taken together, our results demonstrate that DMT treatment activates the subgranular neurogenic niche regulating the proliferation of neural stem cells, the migration of neuroblasts, and promoting the generation of new neurons in the hippocampus, therefore enhancing adult neurogenesis and
    [Show full text]
  • Serotonin Biosynthesis Neurotransmitters Module: the Beery Twins’ Story© a Project-Based Learning Activity
    Serotonin Biosynthesis Neurotransmitters Module: The Beery Twins’ Story© A Project-Based Learning Activity Sepiapterin reductase is the final enzyme in the biosynthetic pathway for tetrahydrobiopterin – a cofactor used by other enzymes in the synthesis of the neurotransmitters dopamine and serotonin. In the case of serotonin biosynthesis, the enzyme tryptophan hydroxylase uses tetrahydrobiopterin to convert tryptophan to 5-hydroxytryptophan (5-HTP). In a second reaction, the enzyme aromatic L-amino acid decarboxylase converts 5-HTP into serotonin, the active neurotransmitter. Enzymes Neurotransmitters Cofactors Tetrahydrobiopterin Pathway Serotonin Pathway Guanosine Triphosphate (GTP) Tryptophan GTP Cyclohydrolase I (GCH1) Tryptophan Hydroxylase (TPH) with Tetrahydrobiopterin Cofactor Pyruvoyl-Tetrahydropterin Synthase (PTPS) 6-Pyruvoyl-tetrahydropterin 5-Hydroxytryptophan (5-HTP) Aromatic L-Amino Acid Decarboxylase (AAAD) Sepiapterin Reductase (SPR) with Vitamin B6 Cofactor Tetrahydrobiopterin Serotonin Version 1.4 -12/2015 ...where molecules become real TM http://cbm.msoe.edu www.3dmoleculardesigns.com Serotonin Biosynthesis Model Guide Neurotransmitters Module: The Beery Twins’ Story© A Project-Based Learning Activity TPH AAAD Tryptophan 5-Hydroxytryptophan Serotonin Tryptophan (Trp or W) is one of the 20 standard 5-Hydroxytryptophan, an intermediate The nal step in the serotonin biosynthesis amino acids and is an essential amino acid that molecule in the serotonin biosynthesis pathway requires the removal of the cannot be synthesized by the human body. pathway, is formed by the addition of a carboxylic acid group (COOH) from the Tryptophan is composed of the standard amino hydroxyl (OH) group to the fth carbon of the backbone of 5-hydroxytryptophan to form acid backbone with an indole ring side chain. indole ring of tryptophan.
    [Show full text]
  • Monoamine Biosynthesis Via a Noncanonical Calcium-Activatable Aromatic Amino Acid Decarboxylase in Psilocybin Mushroom
    Monoamine Biosynthesis via a Noncanonical Calcium-Activatable Aromatic Amino Acid Decarboxylase in Psilocybin Mushroom The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Torrens-Spence, Michael Patrick et al. "Monoamine Biosynthesis via a Noncanonical Calcium-Activatable Aromatic Amino Acid Decarboxylase in Psilocybin Mushroom." ACS chemical biology 13 (2018): 3343-3353 © 2018 The Author(s) As Published 10.1021/acschembio.8b00821 Publisher American Chemical Society (ACS) Version Author's final manuscript Citable link https://hdl.handle.net/1721.1/124629 Terms of Use Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. Articles Cite This: ACS Chem. Biol. XXXX, XXX, XXX−XXX pubs.acs.org/acschemicalbiology Monoamine Biosynthesis via a Noncanonical Calcium-Activatable Aromatic Amino Acid Decarboxylase in Psilocybin Mushroom † ∇ † ‡ § ∇ † † ∥ Michael Patrick Torrens-Spence, , Chun-Ting Liu, , , , Tomaś̌Pluskal, Yin Kwan Chung, , † ‡ and Jing-Ke Weng*, , † Whitehead Institute for Biomedical Research, 455 Main Street, Cambridge, Massachusetts 02142, United States ‡ Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States § Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States ∥ Division of Life Science, Hong Kong University of Science & Technology, Clear Water Bay, Hong Kong, China *S Supporting Information ABSTRACT: Aromatic L-amino acid decarboxylases (AAADs) are a phylogenetically diverse group of enzymes responsible for the decarboxylation of aromatic amino acid substrates into their corresponding aromatic arylalkylamines. AAADs have been extensively studied in mammals and plants as they catalyze the first step in the production of neurotransmitters and bioactive phytochemicals, respectively.
    [Show full text]
  • The Structure of Dimethylallyl Tryptophan Synthase Reveals a Common Architecture of Aromatic Prenyltransferases in Fungi and Bacteria
    The structure of dimethylallyl tryptophan synthase reveals a common architecture of aromatic prenyltransferases in fungi and bacteria Ute Metzgera,1, Christoph Schallb,1, Georg Zocherb, Inge Unso¨ lda, Edyta Stecc, Shu-Ming Lic, Lutz Heidea,2, and Thilo Stehleb,d aPharmazeutisches Institut, Universita¨t Tu¨ bingen, 72076 Tu¨bingen, Germany; bInterfakulta¨res Institut fu¨r Biochemie, Universita¨t Tu¨ bingen, 72076 Tu¨bingen, Germany; cInstitut fu¨r Pharmazeutische Biologie, Universita¨t Marburg, 35037 Marburg, Germany; and dDepartment of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 37232 Edited by Arnold L. Demain, Drew University, Madison, NJ, and approved July 9, 2009 (received for review May 5, 2009) Ergot alkaloids are toxins and important pharmaceuticals that are farnesyl diphosphate synthase (11, 12), DMATS does not require produced biotechnologically on an industrial scale. The first com- magnesium or other divalent cations for its enzymatic activity, mitted step of ergot alkaloid biosynthesis is catalyzed by dimethy- although addition of 4 mM CaCl2 moderately increases its reaction lallyl tryptophan synthase (DMATS; EC 2.5.1.34). Orthologs of velocity (10). The structural gene coding for DMATS in Claviceps, DMATS are found in many fungal genomes. We report here the termed dmaW, was identified by Tsai et al. (13). A similar gene, x-ray structure of DMATS, determined at a resolution of 1.76 Å. A fgaPT2, exists in the biosynthetic gene cluster of fumigaclavine, in complex of DMATS from Aspergillus fumigatus with its aromatic the genome sequence of A. fumigatus. Expression of the DMATS substrate L-tryptophan and with an analogue of its isoprenoid sequence from A.
    [Show full text]
  • Recreational Use, Analysis and Toxicity of Tryptamines
    Send Orders for Reprints to [email protected] 26 Current Neuropharmacology, 2015, 13, 26-46 Recreational Use, Analysis and Toxicity of Tryptamines Roberta Tittarelli1, Giulio Mannocchi1, Flaminia Pantano1 and Francesco Saverio Romolo1,2,* 1Legal Medicine Section, Department of Anatomical, Histological, Forensic Medicine and Orthopedic Sciences, “Sapienza” University of Rome, Viale Regina Elena, 336, 00161 Rome, Italy; 2Institut de Police Scientifique, Université de Lausanne, Batochime, 1015 Lausanne, Switzerland Abstract: The definition New psychoactive substances (NPS) refers to emerging drugs whose chemical structures are similar to other psychoactive compounds but not identical, representing a “legal” alternative to internationally controlled drugs. There are many categories of NPS, such as synthetic cannabinoids, synthetic cathinones, phenylethylamines, piperazines, ketamine derivatives and tryptamines. Tryptamines are naturally occurring compounds, which can derive from the amino acid tryptophan by several biosynthetic pathways: their structure is a combination of a benzene ring Roberta Tittarelli and a pyrrole ring, with the addition of a 2-carbon side chain. Tryptamines include serotonin and melatonin as well as other compounds known for their hallucinogenic properties, such as psilocybin in ‘Magic mushrooms’ and dimethyltryptamine (DMT) in Ayahuasca brews. Aim: To review the scientific literature regarding tryptamines and their derivatives, providing a summary of all the available information about the structure of these compounds, their effects in relationship with the routes of administration, their pharmacology and toxicity, including articles reporting cases of death related to intake of these substances. Methods: A comprehensive review of the published scientific literature was performed, using also non peer-reviewed information sources, such as books, government publications and drug user web fora.
    [Show full text]